Critical Reviews in Oncology / Hematology
Volume 74, Issue 1 , Pages 16-26 , April 2010

Integration of panitumumab into the treatment of colorectal cancer

  • Cristina Gravalos

      Affiliations

    • Medical Oncology Department, University Hospital “12 de Octubre”, Avda. de Andalucía s/n Km 5.400, 28041 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 91 390 83 49; fax: +34 91 460 33 10.
    • ,
  • Javier Cassinello

      Affiliations

    • Medical Oncology Department, University Hospital of Guadalajara, Guadalajara, Spain
    • ,
  • Pilar García-Alfonso

      Affiliations

    • Medical Oncology Department, University Hospital of Gregrorio Marañón, Madrid, Spain
    • ,
  • Antonio Jimeno

      Affiliations

    • University of Colorado Cancer Center, Aurora, CO, USA

,Accepted 18 June 2009.

References 

  1. Kamangar F, Dores GM, Anderson WF. Patterns of care incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic region of the world. J Clin Oncol. 2006;26:2137–2150
  2. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947
  3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041–1047
  4. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  5. Capdevila J, Saura C, Macarulla T, et al. Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol. 2007;33(Suppl 2):S24–S34
  6. Salomon DS, Brandt R, Ciardello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232
  7. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958–2970
  8. http://www.emea.europa.eu/humandocs/Humans/EPAR/erbitux/erbitux.htm
  9. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17–23
  10. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004;58:984–990
  11. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999;59:1236–1243
  12. Freeman D, McDorman K, Bush T, et al. Mono- and combination-therapeutic activity of panitumumab on human A431 epidermoid and HT-29 colon carcinomas xenografts: correlation with pharmacodynamic parameters. Eur J Cancer Suppl. 2004;Abstr 95
  13. http://www.emea.europa.eu/humandocs/Humans/EPAR/vectibix/vectibix.htm
  14. Weiner LM, Belldegrun AS, Crawford J, et al. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008;14:502–508
  15. Stephenson JJ, Cohn A, Crawford J, et al. Administration of panitumumab (Pmab) every two weeks (Q2W) as a 30-min or 60-min infusion: safety and pharmacokinetics (PK) from a phase 1 study in patients with solid tumors. Gastrointestinal Cancers Symposium, Orlando, 2007; Abstr. 368.
  16. Wainberg ZA, Hecht JR. Panitumumab in colorectal cancer. Expert Rev Anticancer Ther. 2007;7:967–973
  17. Committee for Proprietary Medicinal Products (CPMP). European Public Assessment Report (EPAR). Vectibix®. http://www.emea.europa.eu/humandocs/Humans/EPAR/vectibix/vectibix.htm. Accessed on March 31, 2008.
  18. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110:980–987
  19. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mmCRC) expressing≥10% epidermal growth factor receptor (EGFR). American Society of Clinical Oncology, Orlando, 2006; Abstr. 3548.
  20. Hecht R, Mitchell EP, Baranda J, et al. Panitumumab (Pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy and KRAS analyses. Gastrointestinal Cancers Symposium, Orlando, 2008; Poster 343.
  21. Yoshino T, Muro K, Doi T, et al. Phase 2 study of Panitumumab (Pmab) monotherapy in Japanese patients (pts) with metastatic colorectal cancer (mCRC) after the failure of fluoropyrimidine, irinotecan (CPT-11) and oxaliplatin (OHP) chemotherapy. Gastrointestinal Cancers Symposium, Orlando, 2008; Abstr. 366.
  22. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–1664
  23. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008;19:92–98
  24. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:427–432
  25. Siena S, Tabernero J, Burkes RL, et al. Phase III study (PRIME/200505203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data. J Clin Oncol. 2008;26:Abstr. 4034
  26. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2008;27:672–680
  27. Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008;19(4):734–738
  28. Peeters M, Wilson G, Ducreux M, et al. Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. American Society of Clinical Oncology, Chicago, 2008; Abstr. 4064.
  29. Mitchell EP, LaCouture ME, Shearer H, et al. Phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer patients (pts) receiving panitumumab (pmab)+FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis. American Society of Clinical Oncology, Chicago, 2008; Abstr. 15007.
  30. Mitchell EP, LaCouture ME, Shearer H, et al. A phase II, open-label, randomized clinical trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving 2nd line FOLFIRI or irinotecan-only chemotherapy (CT) with panitumumab (pmab): Early analysis. Gastrointestinal Cancers Symposium, Orlando, 2008; Poster 462.
  31. Asmis TR, Shah MA, Haviland D, Kemeny N. Panitumumab with or without chemotherapy in metastatic colorectal cancer (mCRC): Safety and unusual activity, even following progression on cetuximab. Gastrointestinal Cancers Symposium, Orlando, 2008; Abstr. 484.
  32. Peeters M, Van Cutsem E, Berlin J, et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. American Society of Clinical Oncology, Chicago, 2007; Abstr. 4138.
  33. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634
  34. Hecht R, Mitchell EP, Baranda J, et al. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy and KRAS analyses. Gastrointestinal Cancers Symposium, Orlando, 2008; Poster 343.
  35. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–515
  36. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166–1169
  37. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–2648
  38. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230–3237
  39. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Eng J Med. 2008;359:1757–1765
  40. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–5712
  41. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–286
  42. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007;25:3228–3245
  43. Humblet Y, Peeters M, Siena S, et al. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). American Society of Clinical Oncology, Chicago, 2007; Abstr. 4038.
  44. Michelini T, Hecht JR, Peeters M, et al. Pooled analysis of five clinical trials examining the predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC). American Society of Health-System Pharmacists, Las Vegas, 2007; P141D.
  45. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Eng J Med. 2007;357(20):2040–2048
  46. Van Cutsen E, Kohne C-H, Hitre EH, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417
  47. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, Leucovorin and Oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–671

PII: S1040-8428(09)00125-5

doi: 10.1016/j.critrevonc.2009.06.005

Critical Reviews in Oncology / Hematology
Volume 74, Issue 1 , Pages 16-26 , April 2010

Article Tools

* Image Usage & Resolution